MedPath

The Effect of Chronic Remote Ischaemic Preconditioning on Blood Pressure in Older Adults

Not Applicable
Recruiting
Conditions
Hypertension
Vascular Diseases
Interventions
Device: Remote Ischaemic Preconditioning
Device: Sham Remote Ischaemic Preconditioning
Registration Number
NCT05971407
Lead Sponsor
University of Nottingham
Brief Summary

The purpose of this study is to assess whether remote ischaemic conditioning, applied chronically, improves vascular health in older adults

Detailed Description

Hypertension and stroke remain leading causes of mortality across the world (1). Hypertension affects more than 1 in 4 adults and is the 3rd biggest risk factor for premature death and disability in the UK (2). Cerebrovascular disease is ranked 4th in the list of leading causes of death in the UK (3). At present, the treatment of these conditions largely involves chronic pharmacotherapy. In parallel, it is increasingly appreciated that polypharmacy poses a significant challenge to our older adult population. Guthrie et al showed that the number of people prescribed \>5 medications in an area of the UK doubled between 1995 and 2010 (from 11.4% to 20.8%) (4). Age is significantly associated with polypharmacy, with an odds ratio of 118.3 when those aged 20-29 are compared to those \>80. What's more, it has been estimated that adverse drug reactions account for 6.5% of hospital admissions (5), with age correlating significantly with admissions for this reason. Therefore, discovering a non-pharmacological intervention for hypertension and cerebrovascular disease could greatly benefit the population, particularly the elderly, both in terms of treating the diseases themselves and reducing the harmful effects of polypharmacy.

Remote ischaemic preconditioning (RIPC) is the induction of non-lethal ischaemia in one organ or tissue, with the aim of conditioning a distant organ or tissue against ischaemic events. It is achieved via inflation of a blood pressure cuff to supra-systolic pressures for a short period of time. A recent meta-analysis showed that chronic RIC, but not acute RIC, significantly lowered diastolic and mean arterial blood pressure (6). The studies included in this review were small and performed in a younger population, hence larger studies are needed to clarify the effect of RIC in the field of hypertension and, importantly, the elderly.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Participant is aged >65y and <85y.
  • Participant is willing and able to give informed consent for participation in the study.
  • Participant is physically able to perform RIPC.
Exclusion Criteria
  • A BMI <18 or >35 kg/m2
  • Active cardiovascular, cerebrovascular or respiratory disease: e.g. uncontrolled hypertension (BP > 160/100), active angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event, COPD, pulmonary hypertension or recent (6 mo) stroke.
  • If history of hypertension, no recent alteration to antihypertensive medication (3 months).
  • A history of, or current neurological or musculoskeletal conditions (e.g. epilepsy)
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Remote Ischaemic PreconditioningRemote Ischaemic PreconditioningRIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg above systolic blood pressure. RIPC is conducted 3 times weekly for 6-weeks.
Sham remote ischaemic preconditioningSham Remote Ischaemic PreconditioningSham RIPC is induced by 4 cycles of 5 minutes of healthy upper limb ischaemia followed by 5 minutes reperfusion. Ischaemia is induced by inflation of a blood pressure cuff to 20mmHg. RIPC is conducted 3 times weekly for 6-weeks
Primary Outcome Measures
NameTimeMethod
Clinic systolic blood pressureMeasured at baseline, week 3 and week 6

Changes in blood pressure measured by automated sphygmomanometer over 6 weeks. Measured after participants have rested for 10 minutes in a temperature controlled room.

Secondary Outcome Measures
NameTimeMethod
Clinic Mean arterial pressureMeasured at baseline, week 3 and week 6

Changes in blood pressure measured by automated sphygmomanometer over 6 weeks. Measured after participants have rested for 10 minutes in a temperature controlled room.

24-hour diastolic blood pressureMeasured at baseline and week 6

Changes in blood pressure measured by 24-hour blood pressure monitor.

Clinic diastolic blood pressureMeasured at baseline, week 3 and week 6

Changes in blood pressure measured by automated sphygmomanometer over 6 weeks. Measured after participants have rested for 10 minutes in a temperature controlled room.

24-hour systolic blood pressureMeasured at baseline and week 6

Changes in blood pressure measured by 24-hour blood pressure monitor.

24-hour mean arterial pressureMeasured at baseline and week 6

Changes in blood pressure measured by 24-hour blood pressure monitor.

Flow mediated dilatation (FMD)Measured at baseline, week 3 and week 6

Flow mediated dilatation is measured by continuous ultrasound imaging of the brachial artery. Brachial artery diameter is measured using edge tracking software for one minute before distal occlusion is applied to the brachial artery for 5 minutes at 230mmHg using and automated vascular assessment pressure cuff. Following release of the distal occlusion, flow mediated dilatation is measured for 4 minutes using edge tracking software

Pulsewave velocity (PWV)Measured at baseline, week 3 and week 6

Pulsewave velocity is measured using carotid and femoral artery transducers. Pulse transit time and the distance between transducers is then used to calculate PWV.

Serum biomarkersMeasured at baseline and week 6.

Biomarkers of RIC mechanism will be quantified by ELISA from plasma samples collected before and after intervention.

Trial Locations

Locations (1)

School of Medicine, Royal Derby Hospital Site, University of Nottingham

🇬🇧

Derby, Derbyshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath